Comparing the current results to its competitors, Intest reported Revenue increase in the 1 quarter 2026 by 28.22 % year on year. The sales growth was above Intest's competitors' average revenue growth of 5.88 %, achieved in the same quarter.
Intest's Comment on Competition and Industry Peers
The company manufactures docking hardware products that enable plug-compatibility, allowing customers to use test heads from various brands interchangeably with different probers and handlers by changing only the interface boards. This compatibility enhances the flexibility and utilization of test heads, probers, and handlers from multiple automated test equipment (ATE) manufacturers. The company does not sell probers, handlers, or testers, which facilitates collaboration with ATE manufacturers who provide essential information for designing plug-compatible products. Its tester interface products establish electrical connections between testers and wafer probers or IC handlers, optimizing signal integrity for high-speed, high-frequency, digital, or mixed-signal testing. The company employs approximately 100 engineers dedicated to engineering and product development and occasionally engages third-party consultants. Engineers are assigned to specific customers to support relationship building and product development. The company implements measures to protect its intellectual property but acknowledges that such protections may not prevent competition or imitation of its products or processes.
Park Ohio Industries Inc's business model revolves around providing supply chain logistics services, manufacturing and engineering solutions, and producing highly engineered products to various industries. They operate through multiple business segments, including Supply Technologies, Assembly Components, Engineered Products, and Energy & Real Estate. The company aims to offer comprehensive solutions and value-added services to meet the evolving needs of their customers and maintain long-term relationships with them.
Rani Therapeutics Holdings Inc utilizes a novel approach in developing therapeutics by delivering large molecules orally, avoiding the need for injections.
Sources:
Intest Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intest Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
